Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


The primary cause of gastric cancer is chronic infection with Helicobacter pylori (H. pylori), particularly the high-risk genotype cagA, and risk modification by human genetic variants. We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO). Our population-based, case-control study included 1366 individuals (664 gastric cancer cases and 702 controls) from Western Honduras, a high incidence region of Latin America. CagA seropositivity was strongly associated with cancer (OR = 3.6; 95% CI: 2.6, 5.1). The ODC1 variant rs2302615 was associated with gastric cancer (OR = 1.36; p = 0.018) in a model adjusted for age, sex, and CagA serostatus. Two additional single nucleotide polymorphisms (SNPs) in CASP1 (rs530537) and TLR4 (rs1927914) genes were also associated with gastric cancer in univariate models as well as models adjusted for age, sex, and CagA serostatus. The ODC1 SNP association with gastric cancer was stronger in individuals who carried the TT genotype at the associating TLR4 polymorphism, rs1927914 (OR = 1.77; p = 1.85 × 10-3). In conclusion, the ODC1 variant, rs2302615, is associated with gastric cancer and supports chemoprevention trials with DFMO, particularly in individuals homozygous for the T allele at rs1927914.

Free full text 


Logo of nihpaLink to Publisher's site
Oncogene. Author manuscript; available in PMC 2022 Apr 1.
Published in final edited form as:
PMCID: PMC8692072
NIHMSID: NIHMS1762874
PMID: 34376808

Ornithine Decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus

Abstract

The primary cause of gastric cancer is chronic infection with Helicobacter pylori (H. pylori), particularly the high-risk genotype cagA, and risk modification by human genetic variants. We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO). Our population-based, case-control study included 1366 individuals (664 gastric cancer cases and 702 controls) from Western Honduras, a high incidence region of Latin America. CagA seropositivity was strongly associated with cancer (OR = 3.6; 95% CI: 2.6, 5.1). The ODC1 variant rs2302615 was associated with gastric cancer (OR = 1.36; p = 0.018) in a model adjusted for age, sex, and CagA serostatus. Two additional single nucleotide polymorphisms (SNPs) in CASP1 (rs530537) and TLR4 (rs1927914) genes were also associated with gastric cancer in univariate models as well as models adjusted for age, sex, and CagA serostatus. The ODC1 SNP association with gastric cancer was stronger in individuals who carried the TT genotype at the associating TLR4 polymorphism, rs1927914 (OR = 1.77; p = 1.85 × 10−3). In conclusion, the ODC1 variant, rs2302615, is associated with gastric cancer and supports chemoprevention trials with DFMO, particularly in individuals homozygous for the risk allele, C, at rs2302615.

Keywords: Ornithine decarboxylase, gastric cancer, H. pylori, CagA, SNP, Central America, Honduras

INTRODUCTION

Gastric adenocarcinoma is the third leading cause of global cancer mortality, and the leading infection-associated cancer, driven by chronic infection with Helicobacter pylori.(1, 2) There is also remarkable geographic variability of gastric cancer (GC) with respect to both incidence(3) and mortality.(4) Latin America has among the highest GC incidence rates in the world. There is an excess burden in the mountainous regions along the Pacific littoral as compared with coastal populations, even though the two regions have high endemic H. pylori infection; this has been termed the “Latin American altitude enigma”.(3) Altitude appears to be a surrogate for the clustering in the mountain villages of high-risk interactions between host genetic and H. pylori genetic factors(5), with modulation by dietary and environment factors.(6)

In the United States, GC represents a marked cancer disparity, with an excess burden among minorities. The GC incidence is approximately doubled among non-whites, including Hispanics.(7) Notably, immigrants from high GC incidence areas are at-risk. Those who emigrate from high-to-low incidence regions maintain the risk of their nation of origin, most likely due to ‘importing’ their host and H. pylori genetic risks.(8)

The gastric carcinogenesis pathway is a multifactorial process that progresses from pre-malignant to malignant phenotypes through several histopathology stages: normal mucosa, chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and adenocarcinoma.(9) Progression is driven by host genetics and H. pylori virulence and oncogenic factors, as well as dietary and environmental influences. H. pylori accounts for much of the attributable risk with cagA being the principal H. pylori risk genotype, and the CagA protein as the dominant virulence factor for gastric adenocarcinoma.(10-14)

Human germline mutations are thought to be important drivers in up to 10-15% of incident GC cases.(15) An elevated risk of GC has been associated with gene polymorphisms including those in the inflammation pathway, such as genes encoding IL-1β, TNF-α, and IL-10.(12, 16, 17) Additionally, associations between GC and variants in PSCA and MUC1 (18-20), and at a locus that includes PRKAA1 and PTGER4 (20, 21) have been detected in genome-wide association studies of GC in Asian populations. Few studies have explicitly examined the host genetic basis for GC in Latin American populations.(22) The interaction of genetic variants in both the host and H. pylori affect disease progression and may explain some of the geographic variation in GC risk, yet the specific human loci and their relationship to disease risk remain poorly understood.(5, 23, 24)

Knowledge of human cancer risk loci may identify at-risk populations and has potential for targeting chemoprevention. For example, in colorectal cancer with the adenoma precursor lesion, there are potential targeted treatments for chemoprevention such as those based on ornithine decarboxylase (ODC1) gene variants. The ODC enzyme converts L-ornithine to the first polyamine putrescine.(25, 26) Putrescine is sequentially converted into the polyamines spermidine and spermine via spermidine synthase (SRM) and spermine synthase (SMS), respectively; both reactions require the donation of an aminopropyl group from decarboxylated S-adenosylmethionine (dcSAM), which is synthesized by the sequential conversion of i) methionine to S-adenosylmethionine (SAM) by S-adenosylmethionine synthase (METK) and ii) SAM to dcSAM by S-adenosylmethionine decarboxylase (SAMDC), encoded by AMD1.(27) Polyamines are essential for cellular growth and survival and are important in the development of the GI tract and the immune system.

In humans, an ODC1 variant, rs2302615, has been associated with adenoma risk, as well as an augmented chemoprevention response to alpha-difluoromethylornithine (DFMO). Patients with the CC genotype have a higher risk of colon adenomas, yet are more responsive to DFMO and sulindac.(28, 29) This ODC1 SNP is located in intron 1, a region known to affect ODC1 transcription (28), but no data exists on the relationship of this polymorphism and human GC. However, this gene may also be relevant to GC as myeloid-cell specific deletion of the Odc1 gene in mice results in enhanced host immune response to H. pylori and diminished bacterial load in the stomach.(30) H. pylori-induced ODC activity is associated with macrophage apoptosis.(26, 31) In addition, studies have identified variants in ODC pathway genes that associate with GC.(32) Based on these prior studies, we hypothesized that ODC1, and rs2302615 in particular, which associates with transcription, will affect the risk for GC.

In addition to evaluating the ODC1 variant described above, we analyzed 93 candidate single nucleotide polymorphisms (SNPs) in 53 genes potentially linked to GC based on prior association studies of gastric cancer and gastritis.(33-39) These markers have largely been studied in European and East Asian populations, with few studies in high risk Latin American populations. They fall into classes related to mechanisms of inflammation, immunity, H. pylori colonization, and oxidative stress (40-44), as well as many of the dietary and environmental markers associated with disease, but some do not have a clear mechanism.(6, 45)

Our study aimed at determining patterns of genetic association in the mountainous regions of Western Honduras, where the GC incidence is among the highest in Latin America.(3) We assessed if the genotypes of the ODC1 SNP, rs2302615, were associated with GC in the high-risk Western Honduran population and in what context they were the most strongly associated. We also examined the other SNPs with known significance in GC and asked if putative association of the other SNPs was modified by the ODC1 genotype risk.

RESULTS

Of the 1500 individuals in this population-based, case-control study in Honduras, complete genetic data were available for 1366 participants. The mean ages of GC cases and controls were 63.8 and 53.6 years, respectively. Males comprised 70% (n= 468) and 50% (n= 350) of cases and controls, respectively. H. pylori and CagA seropositive cases were determined by a multiplex serology (see Methods). Overall, a high H. pylori prevalence was confirmed, detected in 90.5% and 88.2% of cases and controls, respectively. H. pylori CagA seropositivity was 87% and 73.6% in cases and controls, respectively, and strongly associated with GC in the unadjusted analysis (Odds Ratio, OR = 3.59; 95% CI 2.56, 5.11; p = 6.0 × 10−14; Table 1).

Table 1.

Selected characteristics of gastric cancer cases and population controls

CharacteristicsOverall
(N=1366)
Gastric Cancer Cases
(N=664)
Healthy Control
Population (N=702)
P-value
Age < 2 X 10−16
 Mean in years (SD)*58.5 (16.1)63.78 (13.7)53.52 (16.5)
Sex, n (%) 1.34 X 10-14
 Male818 (60%)468 (70%)350 (50%)
 Female548 (40%)196 (30%)352 (50%)
H. pylori serostatus, n (%) 0.009
 Positive1220 (89.3%)601 (90.5%)619 (88.2%)
 Negative78 (5.7%)26 (3.9)52 (7.4%)
 Missing68 (4.98%)37 (5.6%)31 (4.4%)
CagA serostatus, n (%) 6.0 X 10-14
 Positive1095 (80.2%)578 (87.0%)517 (73.6%)
 Negative202 (14.8%)48 (7.2%)154 (21.9%)
 Missing69 (5.05%)38 (5.7%)31 (4.4%)

Notes:

*Standard deviation (SD)

Of the 94 selected SNPs, one SNP, rs4072037, was out of Hardy–Weinberg equilibrium (p < 1.0 × 10−16 for both cases and controls), indicating a likely genotyping error, and was excluded from the analyses. In addition, 11 SNPs were excluded with a minor allele frequency of less than 0.05 (Table S1, Table S2). Linkage Disequilibrium (LD) was detected between 20 SNP pairs in which 4 SNPs appeared in two pairs. A total of 28 SNPs were excluded, resulting in 66 SNPs for the final analysis (Table S3, Figure S1). Using the Benjamini-Hochberg FDR multiple test correction with α = 0.1, resulted in a multiple testing threshold of p = 0.021 (raw value).

Cases were associated with ODC1 genotype considered as cancer risk (CC) or protective (CT/TT) based on the colon cancer literature using a chi-square analysis (p = 0.021).(46-48) In the unadjusted logistic regression model, the ODC1 SNP was associated with GC (OR=1.21, 95% CI 1.14, 1.80; p=0.027). In the model adjusted for age, sex, and CagA status, and FDR corrected for multiple testing, the ODC1 SNP was significantly associated with GC (OR = 1.36, 95% CI 1.05, 1.76; p=0.018) (Table 2, Table S4).

Table 2.

Associations of single nucleotide polymorphisms (SNPs) with gastric cancer risk

ChromosomeSNPGeneMajor alleleMinor alleleMAFUnadjusted OR (95% CI)p-valueAdjusted* OR (95% CI)p-value*
2rs2302615 ODC1 CTa0.2641.21 (1.14, 1.80)0.027 1.36 (1.05, 1.76) 0.018
9rs1927914 TLR4 TaC0.365 1.33 (1.13, 1.54) 0.0004 1.23 (1.03, 1.47) 0.021
11rs530537 CASP1 AaG0.499 1.30 (1.11, 1.51) 0.0007 1.23 (1.03, 1.45) 0.019
2rs1056836 CYP1B1 CaG0.246 0.75 (0.63, 0.89) 0.001 0.81 (0.66, 0.99)0.036
2rs1800440 CYP1B1 AaG0.094 0.71 (0.55, 0.93) 0.011 0.74 (0.55, 0.98)0.04
3rs35683 GHRL CaA0.276 0.81 (0.69 0.96) 0.015 0.85 (0.71, 1.03)0.096
4rs4129009 TLR10 AaG0.107 0.73 (0.57, 0.94) 0.014 0.79 (0.59, 1.04)0.089
8rs2294008 PSCA TaC0.322 0.81 (0.68, 0.95) 0.009 1.13 (0.74, 1.06)0.197

Notes:

areferent allele
*Adjusted for age, sex, and cagA serostatus, with respective ORs age (OR 1.03, 95% CI 1.02, 1.04), sex (OR 2.65, 95% CI 1.91, 3.71), and CagA (OR 3.16, 95% CI, 1.93, 5.26)

Odds ratio (OR) only included if p <0.10 and bolded SNPs pass FDR cut off (p <0.021) and are for the dominant model

Of the remaining 65 SNPs, initial unadjusted association analyses identified seven SNPs with risk or protective associations with GC where the major allele was used as the reference. In an additive regression model, GC was associated with rs35686 in the ghrelin and obestatin prepropeptide (GHRL) gene, (p = 0.015), rs4129009 in toll-like receptor-10 (TLR10) (p = 0.014), rs2294008 in prostate stem cell antigen (PSCA) (p = 0.009), rs1927914 in toll-like receptor-4 (TLR4) (p = 0.0004), and rs530537 in caspase-1 (CASP1) (p = 0.0007) (Table 2). Lastly, two SNPs, rs1056836 and rs1800440, in cytochrome P450 family 1 subfamily B member 1 (CYP1B1) were both associated with GC (p = 0.001 and p = 0.011, respectively) (Table 2). The two CYP1B1 SNPs are not in LD (R2 = 0.034). In the models adjusted for age, sex, and bacterial CagA serostatus, only the SNPs in the TLR4 and CASP1 genes remained significant: TLR4 (OR = 1.23; p = 0.021) and CASP1 (OR = 1.23; p = 0.019) (Table 2, Table S5).

In the final model with the three SNPs (ODC1, TLR4, CASP1) and adjusted for age, sex, and CagA serostatus, only the ODC1 SNP remained significant (OR = 1.35; p = 0.021), as well as age (OR 1.03, 95% CI 1.02, 1.04), sex (OR 2.65, 95% CI 1.91, 3.71), and CagA (OR 3.16, 95% CI, 1.93, 5.26). SNPs in TLR4 (OR = 1.04; p = 0.30) and CASP1 (OR = 1.02; p = 0.27) were not significant in the final model. There were no detected interactions between CASP1 and ODC1 (OR = 1.02; p = 0.68) nor TLR4 and ODC1 (OR = 1.04; p = 0.52). However, noting the effects of the TLR4 and CASP1 loci on ODC1-related risk, we performed stratified analyses on the subsets of these two loci to assess how ODC1 risk changes among strata. The effect of the ODC1 genotype in the TLR4 TT subset alone (n = 563; OR = 1.77; p =1.85 × 10−3) was significant, and with a larger effect size (Table S6).

We also performed a stratified analysis restricting to the 1095 high-risk individuals who were CagA seropositive. Unadjusted analysis of these individuals were significant (p < 0.021) for the previously identified SNPs: rs1927914/TLR4 (OR = 1.34; p = 0.005), rs1056836/CYP1B1 (OR = 0.77; p = 0.008), and rs2302615/ODC1 (OR = 1.35; p = 0.020). One additional SNP was identified in this high-risk cohort, rs4129009/TLR10, also passed the FDR threshold (OR = 0.717; p = 0.018). The ORs were of similar magnitude and size in the unadjusted and adjusted models for all individuals (Table 2, Table 3).

Table 3.

Associations of single nucleotide polymorphisms (SNPs) with gastric cancer risk among CagA-seropositive cases and controls

ChromosomeSNPGeneAdjusted
OR (95%
CI)*
p-
value
1rs1801131 MTHFR 0.835
1rs1801133 MTHFR 0.428
1rs1846522 FAF1 0.36
1rs1137101 LEPR 0.95
1rs5845 SELENOF 0.65
1rs1800871 IL10 0.566
1rs1800896 IL10 0.543
2 rs2302615 ODC1 1.36 (1.05, 1.75) 0.02
2rs1800440 CYP1B1 0.77 (0.54, 1.02)0.069
2 rs1056836 CYP1B1 0.77 (0.57, 0.95) 0.008
2rs10197208 GKN3P 0.655
2rs1143634 IL1B 0.982
2rs1143627 IL1B 0.257
2rs16944 IL1B 0.206
2rs419598 IL1RN 0.913
2rs1063728 RPRM 0.873
2rs61261057 UGT1A10 0.969
2rs17868323 UGT1A10 0.291
2rs11692021 UGT1A10 0.54 (0.69, 1.03)0.096
3rs35683 GHRL 0.81 (0.67, 0.97)0.024
3rs9841504 ZBTB20 0.452
4 rs4129009 TLR10 0.72 (0.54, 0.94) 0.018
4rs4543123 TLR1 0.81 (0.65, 1.00)0.053
4rs5743604 TLR1 0.15 (0.97, 1.36)0.099
4rs6815814 TLR1 0.389
4rs4588 GC 0.364
4rs7041 GC 0.596
4rs4073 CXCL8 0.47
5rs13361707 PRKAA1 0.095
5rs7579 CCDC152 0.687
5rs3877899 CCDC152 0.751
6rs3020314 ESR1 0.492
6rs4880 SOD2 0.344
7rs2066853 AHR 0.284
7rs1800795 IL6 0.235
8rs5030839 NAT1 0.572
8rs15561 NAT1 0.756
8rs1041983 NAT2 0.178
8rs1799929 NAT2 0.186
8rs1799930 NAT2 0.464
8rs1799931 CYP2C9 0.293
8rs2294008 PSCA 0.336
9 rs1927914 TLR4 1.34 (1.08, 1.54) 0.005
9rs505922 ABO 0.277
10rs10508902 ARHGAP22 0.924
10rs2031920 CYP2E1 0.658
11rs12794714 CYPR1 0.937
11rs2060793 CYPR1 0.533
11rs12800438 NADSYN1 1.19 (1.01, 1.42)0.04
11rs3829251 NADSYN1 0.83(0.69,1.01)0.061
11rs530537 CASP1 1.20 (1.01, 1.43)0.034
14rs4986938 ESR2 0.115
14rs1950902 MTHFD1 0.51
14rs2236225 MTHFD1 0.267
15rs762551 CYP1A2 0.391
16rs16260 CDH1 0.83 (0.68, 1.00)0.05
17rs2297518 NOS2 0.588
17rs7220169 GAST 0.832
19rs713041 GPX4 0.653
19rs1800469 B9D2 0.953
20rs13042395 SLC52A3 0.17
20rs6116569 SLC23A2 0.286
20rs6133175 SLC23A2 0.957
20rs6053005 SLC23A2 0.197
20rs17217119 CYP24A1 0.558
21rs225439 TFF3 0.185
*Odds ratio adjusted for age and sex are shown if p <0.10

FDR significant values are bolded (p < 0.021)

A network analysis of gastrointestinal tract tissue was performed for the three genes of interest, TLR4, CASP1, and ODC1. TLR4 and CASP1 were shown to interact (interaction = 0.19). ODC1 had no currently known interaction with TLR4 or CASP1 (Figure S2).

DISCUSSION

We found significant associations of the ODC1 rs2302615 SNP, TLR4 rs1927914, CASP1 rs530537, and H. pylori CagA seropositivity with gastric adenocarcinoma in the rural high incidence region of Western Honduras. The ODC1 rs2302615 SNP is of particular interest as it remained significant when adjusted for the other SNPs and is an actionable SNP previously seen in colorectal cancer.(28) CagA is the principal H. pylori oncogenic virulence factor for GC, and in studies with adjustment for CagA serostatus, the effect sizes of the human genetic variants are usually significantly reduced, (49, 50); however, in our study the effect sizes for H. pylori remained robust for the ODC1 rs2302615 SNP following adjustment.

This is the first study, to our knowledge, demonstrating an association of an ODC1 SNP with GC. Notably, in a Korean cohort investigation, other variants in this pathway were associated with GC, indicating that ODC may play a role in risk even if specific genes and variants differ by population.(21) In conjunction with the colon cancer and gut microbiota literature, these results indicate a broader role for this pathway in gastrointestinal cancers.(21, 51-56) ODC has been shown to contribute to the pathogenesis of colitis and associated carcinogenesis by impairing M1 macrophage responses for antitumor immunity in a mouse model.(57) Loss of ODC in myeloid cells enhances host defense against H. pylori.(30) (58)ODC generates polyamines that regulate the host immune response and is associated with DNA damage, due to the release of hydrogen peroxide by the back conversion of spermine to spermidine by spermine oxidase (SMOX), as spermidine and SMOX are associated with beta-catenin activation in gastric epithelial cells.(59-61) Both our current study and the colon cancer study by Zell et al. report an effect for ODC1 variation but our results were for risk of cancer and theirs was for survival .(47)

In addition to the ODC1 SNP, rs2302615, we found that SNPs in the CASP1 and TLR4 genes were also associated with GC. The ODC1 SNP genotype is highly significant when including covariates age, sex, CagA serostatus, and stronger in the TLR4 TT subset. CASP1 encodes for caspase-1, which is an important inflammasome mediator that cleaves precursors of key inflammatory cytokines into active proteins, including the interleukin-1 family and the pyroptosis inducer gasdermin D. (62-64) These CASP-1-dependent processes are critical in mediating an immune response that effectively dampens H. pylori infection and regulates the host immune response, especially to cagA-positive isolates.(65-70) TLR4 encodes the Toll-like receptor-4, which elicits a strong inflammatory immune response by binding lipopolysaccharide ligands on the surface of Gram-negative bacteria and triggering the MyD88 inflammatory pathway to activate monocytes and neutrophils to clear infections.(71) Variants of TLR4 have been associated with risk for chronic H. pylori infection in multiple studies in humans and mice.(72-74) They have also been implicated in carcinogenesis and metastasis and associated with a broad range of pathology, including recurrent spontaneous miscarriage and diabetic retinopathy in type-2 diabetes.(75, 76) Potential links between TLR4 and CASP1 have been described in human and mouse models in a variety of disease phenotypes, including sterile and infectious inflammatory diseases, idiopathic pulmonary fibrosis, and traumatic spinal cord injury.(77-79) However, there is currently no research that supports a clear functional relationship between ODC1 and either TLR4 or CASP1.

Our findings may have potential GC chemoprevention implications. The administration of DFMO to patients in high-risk GC regions where pre-malignant lesions are prevalent may be warranted. This concept is supported by findings that DFMO significantly attenuates GC development in H. pylori-infected Mongolian gerbils.(59, 60) If the mechanism is similar to colon cancer (28, 29), DFMO could be used for chemoprevention in humans with a precision medicine approach and focused on those with the higher risk CC ODC1 genotype, and especially in those who also have the TLR4 TT genotype, which was observed in 40.6% of the patients in our population. The genotype CC ODC1 and diplotype ODC1 CC/ TLR4 TT have a prevalence of 29.5% and 11.5%, respectively, in the Honduras population.

In summary, our findings suggest that ODC1 genotyping and H. pylori CagA seropositivity is significantly associated with gastric adenocarcinoma in Western Honduras. In addition, its association and potential therapeutic efficacy may be enhanced in those with the TT genotype at TLR4 rs1927914. Nonetheless, replication studies in diverse populations will be necessary to confirm possible generalizability. If confirmed by independent studies, this finding will be an important innovation in guiding a precision-based risk reduction intervention for GC in this and perhaps other high-risk populations and potentially reducing the GC mortality in the high incidence regions of Latin America and Asia.

Subjects and Methods

Study population

We conducted a population-based, case control study in the mountainous region of west-central Honduras. The population is of Hispanic-Mestizo ethnicity and this region has among the highest incidence rates in the western hemisphere, with a high prevalence of chronic H. pylori infection (80-90%).(80) Incident GC cases were enrolled prospectively from the two district hospitals (Santa Rosa de Copán, Siguatepeque) that serve the mountainous rural areas of west-central Honduras. The diagnosis of GC was based on endoscopic appearance and confirmatory histopathology. Household interviews were conducted for the randomly selected controls in the villages in the region.

A novel multiplex serology determined H. pylori and CagA serostatus, the dominant bacterial risk genotype for GC.(39, 81, 82) We focused on CagA, determined by antibodies to this oncoprotein, as the optimal measure of cancer risk with chronic bacterial infection, as well as the high H. pylori prevalence in the region. CagA was measured as part of a larger multiplex serology panel developed by the Germany Cancer Institute (“DKFZ”; TW), the leading panel for H. pylori proteins. In brief, per protocol, the H. pylori proteins were recombinantly expressed as Glutathione-S-transferase (GST)-tag fusion proteins in Escherichia coli BL21 and affinity-purified on glutathione-coated fluorescently labeled polystyrene beads (Luminex Corp.). A mixture of the differently labeled and antigen-loaded beads was then incubated with serum to allow binding of serum antibodies to the H. pylori proteins. Bound serum antibodies were detected by a biotin-labeled anti-human IgM/IgA/IgG secondary antibody and Streptavidin-R-phycoerythrin. A Luminex 200 analyzer (Luminex Corp.) then distinguished between the bead type and consequently the bound antigen as well as quantified the amount of bound serum antibody as median fluorescence intensity (MFI) of 100 beads per type measured. The CagA antigen-specific cutoff was used.(39, 81, 82)

Of the 1500 people enrolled in the case-control study, complete genotyping results were available for 1366 subjects (664 cases, 702 controls). Overall, 89.3% and 80.2% of subjects were seropositive for H. pylori infection and CagA, respectively, as outlined in Table 1. SNPs were chosen in loci in distinct cancer risk pathways (Table S1), including the ODC1 SNP (rs2302615) data that was analyzed both as one of the 94 SNPs and as a covariate, since it has postulated protective effects (CT/TT). The selected SNPs are biased towards coding regions with 17 non-coding SNPs in high LD with both coding and noncoding SNPs (R2 > 0.8) (Table S2, Table S3).

Genetic variant analysis

Human DNA was isolated from whole blood samples with the Qiagen Puregene® kit and genotyped on the sMassARRAY® platform. The ODC1 rs2302615 SNP genotype was determined by TaqMan assay (Thermo Fisher) as it could not be designed with the MassARRAY® technology. Some SNPs were also included as they previously associated with putative disease processes in colon cancer.(83) The 94 hypothesis-driven SNPs fell into four different categories, corresponding to functional SNPs in the GC literature: inflammation and immunity, oncogenic environmental factors, and nutrition (Table S1). (51-56)

Statistical analyses

Using PLINK (version 1.9), 12 of the 94 selected SNPs were removed due to Hardy-Weinberg equilibrium (p < 1.0 × 10−16) or a minor allele frequency less than 0.05 (Table S1, Table S2).(84) Allele frequencies were within the expected ranges, based on the Latin American populations in the 1000 genomes databases.(85) False Discovery Rate (FDR) was used to calculate a threshold for individual SNP significance using the Benjamini-Hochberg test with a FDR level of 0.1 for all tests. Additionally, linkage disequilibrium (LD) was characterized in PLINK and Haploview (version 4.2) among the SNPs regardless of case-control designation to determine the number of independent tests for the FDR threshold.(86) A total of 66 SNPs were considered in the final analysis as linkage disequilibrium (LD) (R2 ≥ 0.9) was detected between 20 SNP pairs in which 4 appeared in two pairs, with 16 total SNPs excluded (Table S3, Figure S1).

Association tests and unadjusted analyses of the final 66 SNPs were performed in PLINK (version 1.9) in a dominant model.(84) Analyses of the resulting SNPs significant at p < 0.1 were analyzed in multivariable logistic regression models for covariates age, sex, CagA serostatus, and ODC1 genotype in R (version 3.6.3). In all cases except one, the referent allele was the major allele; the exception was ODC1 where the prior work on colon cancer indicted that the CC genotype was the risk genotype, but in our population, C was the major allele. Therefore, we used the T allele as the referent for this SNP to assess the risk conferred by the CC genotype in parallel with the prior literature. Covariates were included based on association in the current data and prior studies. Covariates age and sex was expected to influence genetic effects as age positively associates with GC incidence.(87) GC incidence is also notably higher in males, revealing the possible impact of sex hormones on development of gastric disease.(88-90) CagA serostatus was included in all adjusted models as individuals exposed to cagA-positive bacteria associate with increased risk of GC severity.(49, 50) Stratified analyses were restricted to the 1095 individuals carrying cagA-positive bacteria to evaluate the effect of CagA using a univariate analysis. ODC1 status was grouped into genotypes associated with putative risk (CC) or protection (CT/TT) based on previous studies.(28, 47) Logistic regression was used to estimate OR, adjusted for age, sex, CagA serostatus, and ODC1 genotype. SNPs significant individually were also tested in models adjusted for each other models and assessed in stratified analyses.

We also assessed whether genes that showed evidence of significance were related functionally, using the Tissue gene network analysis in HumanBase.(91) This software using machine learning to determine whether there are data driven associations between the genes. We explicitly assessed the relationship between associating genes in the gastrointestinal tract.

Supplementary Material

1762874_Tab~S1

1762874_Tab~S2

1762874_Tab~S3

1762874_Tab~S4

1762874_Tab~S5

1762874_Tab~S6

1762874_Sup_fig

Acknowledgements

We recognize our colleagues in the Hospital de Occidente, Honduras Ministry of Health, and Central America Medical Outreach (CAMO), with special thanks to Lesby Castellanos, Carmen Ramos, Kathy Tschiegg, and Dr. Lia Suazo. We acknowledge the contributions of Dr. Enrique Martinez (Hospital Evangelico, Honduras) and Dr. Michael Pawlita (DKFZ).

Funding

This study was funded in part by the U.S. National Cancer Institute (P01CA028842 (DRM, KTW, SMW), R01CA190612 (DRM, KTW), K07 CA125588 (DRM), PAR-15-155 (DRM), P30CA068485 (DRM, KTW), P01CA116087 (KTW), Veterans Affairs Merit Review grant I01CX002171 (KTW), Department of Defense grant W81XWH-18-1-0301 (KTW), and National Library of Medicine 1R01LM010098 (SMW).

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. SBR, RLD, RM, and DRM had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. DRM had final responsibility for the decision to submit for publication.

Footnotes

Competing Interests

The authors declare that they have no competing interests.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. [Abstract] [Google Scholar]
2. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–e90. [Abstract] [Google Scholar]
3. Torres J, Correa P, Ferreccio C, Hernandez-Suarez G, Herrero R, Cavazza-Porro M, et al. Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America. Cancer Cause Control. 2013;24(2):249–56. [Europe PMC free article] [Abstract] [Google Scholar]
4. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75. [Europe PMC free article] [Abstract] [Google Scholar]
5. Kodaman N, Pazos A, Schneider BG, Piazuelo MB, Mera R, Sobota RS, et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(4):1455–60. [Europe PMC free article] [Abstract] [Google Scholar]
6. Bonequi P, Meneses-Gonzalez F, Correa P, Rabkin CS, Camargo MC. Risk factors for gastric cancer in Latin America: a meta-analysis. Cancer Causes Control. 2013;24(2):217–31. [Europe PMC free article] [Abstract] [Google Scholar]
7. Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, et al. Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018;68(6):425–45. [Abstract] [Google Scholar]
8. Pabla BS, Shah SC, Corral JE, Morgan DR. Increased Incidence and Mortality of Gastric Cancer in Immigrant Populations from High to Low Regions of Incidence: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(2):347–59 e5. [Europe PMC free article] [Abstract] [Google Scholar]
9. Correa P Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev. 1996;5(6):477–81. [Abstract] [Google Scholar]
10. Venerito M, Vasapolli R, Rokkas T, Malfertheiner P. Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. 2018;23 Suppl 1:e12518. [Abstract] [Google Scholar]
11. Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22 Suppl 1. [Abstract] [Google Scholar]
12. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776):398–402. [Abstract] [Google Scholar]
13. Tavera G, Morgan DR, Williams SM. Tipping the Scale Toward Gastric Disease: A Host-Pathogen Genomic Mismatch? Curr Genet Med Rep. 2018;6(4):199–207. [Europe PMC free article] [Abstract] [Google Scholar]
14. Kupfer SS. Gaining Ground in the Genetics of Gastric Cancer. Gastroenterology. 2017;152(5):926–8. [Abstract] [Google Scholar]
15. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55(10):2111–5. [Abstract] [Google Scholar]
16. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124(5):1193–201. [Abstract] [Google Scholar]
17. Tian J, Liu G, Zuo C, Liu C, He W, Chen H. Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies. Cancer Biol Med. 2019;16(2):361–89. [Europe PMC free article] [Abstract] [Google Scholar]
18. Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nature genetics. 2010;42(9):764–7. [Europe PMC free article] [Abstract] [Google Scholar]
19. Study Group of Millennium Genome Project for C, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nature genetics. 2008;40(6):730–40. [Abstract] [Google Scholar]
20. Shi Y, Hu Z, Wu C, Dai J, Li H, Dong J, et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nature genetics. 2011;43(12):1215–8. [Abstract] [Google Scholar]
21. Song HR, Kim HN, Kweon SS, Choi JS, Shim HJ, Cho SH, et al. Genetic variations in the PRKAA1 and ZBTB20 genes and gastric cancer susceptibility in a Korean population. Mol Carcinog. 2013;52 Suppl 1:E155–60. [Abstract] [Google Scholar]
22. Gonzalez-Hormazabal P, Retamales-Ortega R, Musleh M, Bustamante M, Stambuk J, Pisano R, et al. Polymorphisms PSCA rs2294008, IL-4 rs2243250 and MUC1 rs4072037 are associated with gastric cancer in a high risk population. Mol Biol Rep. 2020;47(11):9239–43. [Abstract] [Google Scholar]
23. Snaith A, El-Omar EM. Helicobacter pylori: host genetics and disease outcomes. Expert Rev Gastroenterol Hepatol. 2008;2(4):577–85. [Abstract] [Google Scholar]
24. Kodaman N, Sobota RS, Mera R, Schneider BG, Williams SM. Disrupted human-pathogen co-evolution: a model for disease. Front Genet. 2014;5:290. [Europe PMC free article] [Abstract] [Google Scholar]
25. Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem. 2006;281(21):14529–32. [Abstract] [Google Scholar]
26. Asim M, Chaturvedi R, Hoge S, Lewis ND, Singh K, Barry DP, et al. Helicobacter pylori induces ERK-dependent formation of a phospho-c-Fos c-Jun activator protein-1 complex that causes apoptosis in macrophages. J Biol Chem. 2010;285(26):20343–57. [Europe PMC free article] [Abstract] [Google Scholar]
27. Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61(9):880–94. [Europe PMC free article] [Abstract] [Google Scholar]
28. Zell JA, McLaren CE, Chen WP, Thompson PA, Gerner EW, Meyskens FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. J Natl Cancer Inst. 2010;102(19):1513–6. [Europe PMC free article] [Abstract] [Google Scholar]
29. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A. 2003;100(13):7859–64. [Europe PMC free article] [Abstract] [Google Scholar]
30. Hardbower DM, Asim M, Luis PB, Singh K, Barry DP, Yang C, et al. Ornithine decarboxylase regulates M1 macrophage activation and mucosal inflammation via histone modifications. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(5):E751–E60. [Europe PMC free article] [Abstract] [Google Scholar]
31. Cheng Y, Chaturvedi R, Asim M, Bussiere FI, Scholz A, Xu H, et al. Helicobacter pylori-induced macrophage apoptosis requires activation of ornithine decarboxylase by c-Myc. J Biol Chem. 2005;280(23):22492–6. [Abstract] [Google Scholar]
32. Cho LY, Yang JJ, Ko KP, Ma SH, Shin A, Choi BY, et al. Gene polymorphisms in the ornithine decarboxylase-polyamine pathway modify gastric cancer risk by interaction with isoflavone concentrations. Gastric Cancer. 2015;18(3):495–503. [Abstract] [Google Scholar]
33. Morgan DR, Dominguez RL, Keku TO, Heidt PE, Martin CF, Galanko JA, et al. Gastric cancer and the high combination prevalence of host cytokine genotypes and Helicobacter pylori in Honduras. Clin Gastroenterol Hepatol. 2006;4(9):1103–11. [Abstract] [Google Scholar]
34. Cai H, Ye F, Michel A, Murphy G, Sasazuki S, Taylor PR, et al. Helicobacter pylori blood biomarker for gastric cancer risk in East Asia. Int J Epidemiol. 2016;45(3):774–81. [Europe PMC free article] [Abstract] [Google Scholar]
35. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997;40(3):297–301. [Europe PMC free article] [Abstract] [Google Scholar]
36. Gao L, Weck MN, Michel A, Pawlita M, Brenner H. Association between chronic atrophic gastritis and serum antibodies to 15 Helicobacter pylori proteins measured by multiplex serology. Cancer Res. 2009;69(7):2973–80. [Abstract] [Google Scholar]
37. Weck MN, Gao L, Brenner H. Helicobacter pylori infection and chronic atrophic gastritis: associations according to severity of disease. Epidemiology. 2009;20(4):569–74. [Abstract] [Google Scholar]
38. Epplein M, Zheng W, Xiang YB, Peek RM Jr., Li H, Correa P, et al. Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2185–92. [Europe PMC free article] [Abstract] [Google Scholar]
39. Michel A, Waterboer T, Kist M, Pawlita M. Helicobacter pylori multiplex serology. Helicobacter. 2009;14(6):525–35. [Abstract] [Google Scholar]
40. Hardbower DM, Peek RM Jr., Wilson KT. At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol. 2014;96(2):201–12. [Europe PMC free article] [Abstract] [Google Scholar]
41. Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine. 2005;29(4):141–52. [Abstract] [Google Scholar]
42. Hardbower DM, de Sablet T, Chaturvedi R, Wilson KT. Chronic inflammation and oxidative stress: the smoking gun for Helicobacter pylori-induced gastric cancer? Gut Microbes. 2013;4(6):475–81. [Europe PMC free article] [Abstract] [Google Scholar]
43. Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology. 2002;123(2):542–53. [Abstract] [Google Scholar]
44. Kavermann H, Burns BP, Angermuller K, Odenbreit S, Fischer W, Melchers K, et al. Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J Exp Med. 2003;197(7):813–22. [Europe PMC free article] [Abstract] [Google Scholar]
45. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest. 2007;117(1):60–9. [Europe PMC free article] [Abstract] [Google Scholar]
46. Mondaca S, Yaeger R. Colorectal cancer genomics and designing rational trials. Ann Transl Med. 2018;6(9):159. [Europe PMC free article] [Abstract] [Google Scholar]
47. Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, et al. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res. 2009;15(19):6208–16. [Europe PMC free article] [Abstract] [Google Scholar]
48. Jensen KH, Izarzugaza JMG, Juncker AS, Hansen RB, Hansen TF, Timshel P, et al. Analysis of a gene panel for targeted sequencing of colorectal cancer samples. Oncotarget. 2018;9(10):9043–60. [Europe PMC free article] [Abstract] [Google Scholar]
49. Park JY, Forman D, Waskito LA, Yamaoka Y, Crabtree JE. Epidemiology of Helicobacter pylori and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel). 2018;10(4). [Europe PMC free article] [Abstract] [Google Scholar]
50. Pormohammad A, Ghotaslou R, Leylabadlo HE, Nasiri MJ, Dabiri H, Hashemi A. Risk of gastric cancer in association with Helicobacter pylori different virulence factors: A systematic review and meta-analysis. Microb Pathog. 2018;118:214–9. [Abstract] [Google Scholar]
51. Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis. 2006;27(7):1497–501. [Abstract] [Google Scholar]
52. Haley KP, Gaddy JA. Nutrition and Helicobacter pylori: Host Diet and Nutritional Immunity Influence Bacterial Virulence and Disease Outcome. Gastroenterol Res Pract. 2016;2016:3019362. [Europe PMC free article] [Abstract] [Google Scholar]
53. La Torre G, Chiaradia G, Gianfagna F, De Lauretis A, Boccia S, Mannocci A, et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. Tumori. 2009;95(1):13–22. [Abstract] [Google Scholar]
54. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, et al. The effect of host genetics on the gut microbiome. Nature genetics. 2016;48(11):1407–12. [Abstract] [Google Scholar]
55. Kurilshikov A, Wijmenga C, Fu J, Zhernakova A. Host Genetics and Gut Microbiome: Challenges and Perspectives. Trends Immunol. 2017;38(9):633–47. [Abstract] [Google Scholar]
56. Kolde R, Franzosa EA, Rahnavard G, Hall AB, Vlamakis H, Stevens C, et al. Host genetic variation and its microbiome interactions within the Human Microbiome Project. Genome medicine. 2018;10(1):6. [Europe PMC free article] [Abstract] [Google Scholar]
57. Singh K, Coburn LA, Asim M, Barry DP, Allaman MM, Shi C, et al. Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res. 2018;78(15):4303–15. [Europe PMC free article] [Abstract] [Google Scholar]
58. Hardbower DM, Coburn LA, Asim M, Singh K, Sierra JC, Barry DP, et al. EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis. Oncogene. 2017;36(27):3807–19. [Europe PMC free article] [Abstract] [Google Scholar]
59. Sierra JC, Suarez G, Piazuelo MB, Luis PB, Baker DR, Romero-Gallo J, et al. alpha-Difluoromethylornithine reduces gastric carcinogenesis by causing mutations in Helicobacter pylori cagY. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(11):5077–85. [Europe PMC free article] [Abstract] [Google Scholar]
60. Chaturvedi R, de Sablet T, Asim M, Piazuelo MB, Barry DP, Verriere TG, et al. Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase. Oncogene. 2015;34(26):3429–40. [Europe PMC free article] [Abstract] [Google Scholar]
61. Sierra JC, Piazuelo MB, Luis PB, Barry DP, Allaman MM, Asim M, et al. Spermine oxidase mediates Helicobacter pylori-induced gastric inflammation, DNA damage, and carcinogenic signaling. Oncogene. 2020;39(22):4465–74. [Europe PMC free article] [Abstract] [Google Scholar]
62. Castano-Rodriguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. PLoS One. 2014;9(6):e98899. [Europe PMC free article] [Abstract] [Google Scholar]
63. Li X, Liu S, Luo J, Liu A, Tang S, Liu S, et al. Helicobacter pylori induces IL-1beta and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling pathway. Pathog Dis. 2015;73(4). [Abstract] [Google Scholar]
64. Hitzler I, Sayi A, Kohler E, Engler DB, Koch KN, Hardt WD, et al. Caspase-1 has both proinflammatory and regulatory properties in Helicobacter infections, which are differentially mediated by its substrates IL-1beta and IL-18. J Immunol. 2012;188(8):3594–602. [Abstract] [Google Scholar]
65. Koch KN, Hartung ML, Urban S, Kyburz A, Bahlmann AS, Lind J, et al. Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. The Journal of clinical investigation. 2015;125(8):3297–302. [Europe PMC free article] [Abstract] [Google Scholar]
66. Yang JC, Yang HC, Shun CT, Wang TH, Chien CT, Kao JY. Catechins and Sialic Acid Attenuate Helicobacter pylori-Triggered Epithelial Caspase-1 Activity and Eradicate Helicobacter pylori Infection. Evid Based Complement Alternat Med. 2013;2013:248585. [Europe PMC free article] [Abstract] [Google Scholar]
67. Koch KN, Muller A. Helicobacter pylori activates the TLR2/NLRP3/caspase-1/IL-18 axis to induce regulatory T-cells, establish persistent infection and promote tolerance to allergens. Gut Microbes. 2015;6(6):382–7. [Europe PMC free article] [Abstract] [Google Scholar]
68. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology. 2007;133(1):288–308. [Abstract] [Google Scholar]
69. Peek RM Jr., Miller GG, Tham KT, Perez-Perez GI, Zhao X, Atherton JC, et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest. 1995;73(6):760–70. [Abstract] [Google Scholar]
70. Rolig AS, Cech C, Ahler E, Carter JE, Ottemann KM. The degree of Helicobacter pylori-triggered inflammation is manipulated by preinfection host microbiota. Infect Immun. 2013;81(5):1382–9. [Europe PMC free article] [Abstract] [Google Scholar]
71. Gong Y, Tao L, Jing L, Liu D, Hu S, Liu W, et al. Association of TLR4 and Treg in Helicobacter pylori Colonization and Inflammation in Mice. PLoS One. 2016;11(2):e0149629. [Europe PMC free article] [Abstract] [Google Scholar]
72. Smith SM. Role of Toll-like receptors in Helicobacter pylori infection and immunity. World J Gastrointest Pathophysiol. 2014;5(3):133–46. [Europe PMC free article] [Abstract] [Google Scholar]
73. Su B, Ceponis PJ, Lebel S, Huynh H, Sherman PM. Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect Immun. 2003;71(6):3496–502. [Europe PMC free article] [Abstract] [Google Scholar]
74. Wang TR, Peng JC, Qiao YQ, Zhu MM, Zhao D, Shen J, et al. Helicobacter pylori regulates TLR4 and TLR9 during gastric carcinogenesis. Int J Clin Exp Pathol. 2014;7(10):6950–5. [Europe PMC free article] [Abstract] [Google Scholar]
75. Takenaka R, Yokota K, Ayada K, Mizuno M, Zhao Y, Fujinami Y, et al. Helicobacter pylori heat-shock protein 60 induces inflammatory responses through the Toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiology. 2004;150(Pt 12):3913–22. [Abstract] [Google Scholar]
76. Jin J, Lin F, Liao S, Bao Q, Ni L. Effects of SNPs (CYP1B1*2 G355T, CYP1B1*3 C4326G, and CYP2E1*5 G-1293C), smoking, and drinking on susceptibility to laryngeal cancer among Han Chinese. PloS one. 2014;9(10):e106580. [Europe PMC free article] [Abstract] [Google Scholar]
77. Li W, Bao G, Chen W, Qiang X, Zhu S, Wang S, et al. Connexin 43 Hemichannel as a Novel Mediator of Sterile and Infectious Inflammatory Diseases. Sci Rep. 2018;8(1):166. [Europe PMC free article] [Abstract] [Google Scholar]
78. Terlizzi M, Molino A, Colarusso C, Donovan C, Imitazione P, Somma P, et al. Activation of the Absent in Melanoma 2 Inflammasome in Peripheral Blood Mononuclear Cells From Idiopathic Pulmonary Fibrosis Patients Leads to the Release of Pro-Fibrotic Mediators. Front Immunol. 2018;9:670. [Europe PMC free article] [Abstract] [Google Scholar]
79. Zhu Y, Zhu H, Wang Z, Gao F, Wang J, Zhang W. Wogonoside alleviates inflammation induced by traumatic spinal cord injury by suppressing NF-kappaB and NLRP3 inflammasome activation. Exp Ther Med. 2017;14(4):3304–8. [Europe PMC free article] [Abstract] [Google Scholar]
80. Dominguez RL, Crockett SD, Lund JL, Suazo LP, Heidt P, Martin C, et al. Gastric cancer incidence estimation in a resource-limited nation: use of endoscopy registry methodology. Cancer Causes Control. 2013;24(2):233–9. [Europe PMC free article] [Abstract] [Google Scholar]
81. Varga MG, Wood CR, Butt J, Ryan ME, Youe WC, Pane K, Waterboer T, Epplein M, Shaffer CL. Immunostimulatory membrane proteins potentiate H. pylori-induced carcinogenesis by enabling CagA translocation. Gut Microbes 2021; 13(1): E1862613. [Europe PMC free article] [Abstract] [Google Scholar]
82. Butt J, Blot WJ, Shrubsole MJ, Waterboer T, Pawlita M, Epplein M. Differences in antibody levels to H. pylori virulence factors VacA and CagA among African Americans and whites in the Southeast USA. Cancer Causes Control. 2020;31(6):601–6. [Europe PMC free article] [Abstract] [Google Scholar]
83. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 2010;20(4):440–6. [Europe PMC free article] [Abstract] [Google Scholar]
84. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. [Europe PMC free article] [Abstract] [Google Scholar]
85. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. [Europe PMC free article] [Abstract] [Google Scholar]
86. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5. [Abstract] [Google Scholar]
87. Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of Helicobacter pylori. Gastroenterology. 2006;130(1):65–72; quiz 211. [Abstract] [Google Scholar]
88. de Martel C, Parsonnet J. Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys. Dig Dis Sci. 2006;51(12):2292–301. [Abstract] [Google Scholar]
89. Replogle ML, Glaser SL, Hiatt RA, Parsonnet J. Biologic sex as a risk factor for Helicobacter pylori infection in healthy young adults. Am J Epidemiol. 1995;142(8):856–63. [Abstract] [Google Scholar]
90. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):20–38. [Europe PMC free article] [Abstract] [Google Scholar]
91. Greene CS, Krishnan A, Wong AK, Ricciotti E, Zelaya RA, Himmelstein DS, et al. Understanding multicellular function and disease with human tissue-specific networks. Nat Genet. 2015;47(6):569–76. [Europe PMC free article] [Abstract] [Google Scholar]

Citations & impact 


Impact metrics

Jump to Citations
Jump to Data

Alternative metrics

Altmetric item for https://www.altmetric.com/details/111948184
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/111948184

Article citations

Data 


Data behind the article

This data has been text mined from the article, or deposited into data resources.

Similar Articles 


To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 


Funders who supported this work.

CSRD VA (1)

Crohn's & Colitis Foundation (1)

NCATS NIH HHS (1)

NCI NIH HHS (5)

NHLBI NIH HHS (1)

NIDDK NIH HHS (2)

NIGMS NIH HHS (1)

NLM NIH HHS (1)

U.S. Department of Defense (1)

U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (5)

U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) (1)

U.S. Department of Veterans Affairs (1)